Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis AG

www.novartis.com

Latest From Novartis AG

Atriva Fast Tracks Antiviral Candidate As Coronavirus Arrives In Germany

The antiviral specialist says MEK inhibitor could work against 2019-nCoV, but tests will take time.

International Healthcare Systems

Zolgensma Stands Out In Strong Q4 For Novartis

CEO Vas Narasimhan is confident the Swiss major's gene therapy for spinal muscular atrophy will outperform present and future rivals – Biogen's Spinraza and Roche's risdiplam, respectively – as "we have a better profile simply because we are a one-time therapy."

Sales & Earnings Launches

Torrent Sees Fortunes Affected By Regulatory Overhang

Torrent has tempered FY21 US growth expectations while it plans to put Dahej, Indrad and Levittown plants up for FDA inspection in 2020. Meanwhile, products launched in India, including remoglifozin in-licensed from Glenmark, have shown an encouraging uptake.

Commercial Sales & Earnings

Novartis AveXis President Lennon On Rebuilding Trust With FDA, Zolgensma Trial Hold, And More

AveXis President David Lennon talked to Pink Sheet about quality enhancement at the gene therapy unit, a clinical trial hold for Zolgensma in Type 2 SMA, and expansion in gene therapy.

Gene Therapy Compliance
See All

Company Information

UsernamePublicRestriction

Register